Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GraphyXKRX:318060 -6.65%7 EBITDA Margin % is -73.91% as of Mar. 2026. GuruFocus rates XKRX:318060 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Graphy ranks worse than 76.81% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Graphy's EBITDA for the
three
months ended in Mar. 2026 was ₩-2,479 Mil. Graphy's Revenue for the
three
months ended in Mar. 2026 was ₩3,353 Mil. Therefore, Graphy's EBITDA margin for the quarter that ended in Mar. 2026 was -73.91%.
Graphy (XKRX:318060) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Graphy EBITDA Margin % Related Terms
Graphy EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Graphy's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:318060 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Graphy's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Graphy EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Graphy's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Graphy's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphy (XKRX:318060) has a EBITDA Margin % of -73.91% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Graphy and its competitors. According to the industry distribution chart, Graphy ranks #626 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 76.8%.
Is Graphy's EBITDA Margin % too high?
Graphy's current EBITDA Margin % is -73.91%. Based on the distribution chart, Graphy ranks #626 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Graphy has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Graphy's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Graphy ranks #626 out of 815 companies for EBITDA Margin %. This places Graphy in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Graphy and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Graphy's current EBITDA Margin % is -73.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Graphy stock overvalued right now?
Graphy (XKRX:318060) has a current EBITDA Margin % of -73.91%. The current EBITDA Margin % is -73.91%. Graphy's overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Graphy (XKRX:318060), the current EBITDA Margin % is -73.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Graphy Inc is engaged in developing customized materials (3D printing materials) based on oligomer synthesis technology, photo-curable resins and materials for 3D printing in the dental industry. Its products include Shape Memory Aligner, Permanent C&B, Denture Base, Mouth Guard, and others.
7GF Score
Get the complete analysis for XKRX:318060
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:318060 has been successfully added to your 
